Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Chemomab Therapeutics Ltd. - American Depositary Shares (NQ:CMMB)

2.580 -0.100 (-3.73%)

Streaming Delayed Price Updated: 11:06 AM EST, Nov 13, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	24,211
Open	2.720
Bid (Size)	2.570 (100)
Ask (Size)	2.640 (100)
Prev. Close	2.680
Today's Range	2.570 - 2.735
52wk Range	2.390 - 9.840
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

November 06, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

August 21, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Performance

YTD	-69.7%	-69.7%
1 Month	-23.2%	-23.2%
3 Month	-32.7%	-32.7%
6 Month	-46.7%	-46.7%
1 Year	-65.1%	-65.1%

More News

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 19, 2025

Via Benzinga

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

August 14, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25

June 30, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

June 11, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

June 03, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

May 05, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

April 28, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

April 21, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab Announces New Medical and Clinical Appointments

April 15, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease ↗

March 27, 2025

Via Benzinga

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

March 27, 2025

From Chemomab Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

March 25, 2025

Via Benzinga

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis

March 06, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

March 03, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

February 19, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 03, 2025

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

December 03, 2024

From Chemomab Therapeutics

Via GlobeNewswire

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

November 19, 2024

From Chemomab Therapeutics

Via GlobeNewswire

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

November 14, 2024

From Chemomab Therapeutics

Via GlobeNewswire

Earnings Scheduled For November 14, 2024 ↗

November 14, 2024

Via Benzinga

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

October 30, 2024

From Chemomab Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 15, 2024

Via Benzinga

Frequently Asked Questions

Is Chemomab Therapeutics Ltd. - American Depositary Shares publicly traded?

Yes, Chemomab Therapeutics Ltd. - American Depositary Shares is publicly traded.

What exchange does Chemomab Therapeutics Ltd. - American Depositary Shares trade on?

Chemomab Therapeutics Ltd. - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Chemomab Therapeutics Ltd. - American Depositary Shares?

The ticker symbol for Chemomab Therapeutics Ltd. - American Depositary Shares is CMMB on the Nasdaq Stock Market

What is the current price of Chemomab Therapeutics Ltd. - American Depositary Shares?

The current price of Chemomab Therapeutics Ltd. - American Depositary Shares is 2.580

When was Chemomab Therapeutics Ltd. - American Depositary Shares last traded?

The last trade of Chemomab Therapeutics Ltd. - American Depositary Shares was at 11/13/25 11:06 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.